Acadia Pharma (ACAD) Tops Q4 EPS by 146c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $25.32 +6.75%
Revenue Growth %: +11.8%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +11.8%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $1.60, $1.46 better than the analyst estimate of $0.14. Revenue for the quarter came in at $284 million versus the consensus estimate of $293.78 million.
GUIDANCE:
Acadia Pharma sees FY2026 revenue of $1.22-1.28 billion, versus the consensus of $1.2 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Starts TIME dotCom Berhad (TDC:MK) at Overweight
- JPMorgan Downgrades Astral Ltd (ASTRA:IN) to Neutral
- Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
